Furthermore, our analysis of Orien/cBioPortal data reveals a prognostic implication of LY6E amplification in ovarian cancer, suggesting its potential utility as a biomarker for patient stratification and therapeutic decisions. Here, LY6E is linked to ovarian cancer.